Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (5081)	4/6/1999 2:17:00 PM
From: Condor	Respond to of 57584

BIPL: NEWS (Applies to: BIPL BLUD BLUD) Biopool International Announces Sale of BCA Division VENTURA, CALIF. (April 6) BUSINESS WIRE -April 6, 1999--Biopool International Inc. (Nasdaq:BIPL) Tuesday announced that the company has entered into a definitive agreement to sell its immunohematology (blood-bank reagent) business to Immucor Inc. (Nasdaq:BLUD) of Norcross, Ga. The asset purchase agreement calls for an all-cash transaction for the business operated as Biopool International's "BCA Division," and the transaction is expected to close on or about May 1, 1999. The purchase price is $3.0 million for net working capital plus $1.5 million for the product lines. Biopool will retain ownership of the plant, property and equipment in the West Chester, Pa., facility and will operate the facility on behalf of Immucor during the transition period. With this cash sale and a short-term effort to realize the value in the West Chester facility, Biopool expects to generate a significant amount of liquidity. This new liquidity will position Biopool to take advantage of acquisitions or investments opportunities that will facilitate growth in Biopool's core business segment. Michael D. Bick, Ph.D., chairman and chief executive officer of Biopool, commented: "When we purchased this business in January 1997, we expected to achieve certain synergies between it and Biopool's core hemostasis business. Numerous changes in the dynamics of the blood- bank reagent market have worked against us to realize this ambition. "Immucor has been consolidating the immunohematology business through their acquisition of Dominion Biologicals Ltd. in 1997 and, more recently, by acquiring Gamma Biologicals in November 1998, positioning itself as the market leader for these products in the U.S. Being a distant third in that market dictates that we change our strategy and return our focus to our core hemostasis business." Bick continued, "With the recent U.S. Food and Drug Administration (FDA) clearance of Biopool's APC sensitivity test for determination of thrombotic risk, as well as achieving very significant strides in building upon our D-dimer reagent platform, we need to refocus on building upon Biopool's position as a technological leader in hemostasis and cardiovascular disease, which has consistently been our most profitable business." Immucor, founded in 1982, manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. Founded in 1987, Biopool International develops, manufactures and markets a full range of test kits to assess and diagnose disorders of blood coagulation, thrombotic risk factors, fibrinolysis, platelet function and the vascular system, and specialty chemistry controls used to monitor and measure the presence of drugs of abuse. The company's product line is sold to hospitals, clinical laboratories, commercial reference laboratories and research institutions on a worldwide basis by the company's own sales representatives as well as through an extensive network of distributors. To learn more about Biopool, visit the company's Web site at biopool.com. This news release contains forward-looking statements regarding the generation of significant liquidity and the closing date of a definitive agreement with Immucor, which are based upon current expectations that involve a number of risks and uncertainties, including but not limited to technological innovations of competitors, changes in health-care regulations, litigation claims, foreign- currency fluctuation, product acceptance or changes in government regulation of the company's products, as well as other factors discussed in the company's last report on Form 10-K-SB under "Risk Factors." -0- DB/la* JAP/la CONTACT: Biopool International Inc., Ventura Michael D. Bick or Carol Hill, 805/654-0643 KEYWORD: CALIFORNIA GEORGIA PENNSYLVANIA INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY MERGERS/ACQ Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com

To: Rande Is who wrote (5081)	4/6/1999 2:20:00 PM
From: Condor	Read Replies (2) \| Respond to of 57584

BIPL NEWS from the Buyers side.: (Applies to: BLUD BIPL BLUD) IMMUCOR, INC. SIGNS DEFINITIVE AGREEMENT TO ACQUIRE Biopool's Blood Bank Division NORCROSS, Ga., April 6 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD), a leading provider of blood bank reagents and related products, today announced the signing of a definitive agreement for the purchase of certain assets of the BCA blood bank division of Biopool International Inc. (Nasdaq: BIPL). The acquired product lines currently generate approximately $5.5 million in annual revenues, and are expected to be immediately accretive to Immucor's earnings per share. The purchase price is $3.0 million for net working capital plus $1.5 million for the product lines. The transaction is expected to close on May 1, 1999. Under the terms of the agreement, Biopool will continue to operate the BCA facility on behalf of Immucor during a transition period. Commenting on this transaction Edward L. Gallup, President of Immucor, stated, "As evidenced by our recent acquisitions of Dominion Biologicals Ltd., Gamma Biologicals and Immunochim/Medichim, our French/Belgian distributor, we are implementing our strategy of market consolidation and the establishment of a direct presence in the more important global markets." Gallup further stated, "The purchase of BCA continues our consolidation of the U. S. market as Immucor will now stand as one of only two major players with a complete line of blood bank reagents. Immucor is the market leader in automated instruments and reagents. We believe we are the number one supplier for our field in the North American market and expect this position to strengthen in the future." Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Founded in 1982, Immucor markets a complete family of automated instrumentation for all of our market segments. For more information on Immucor, please visit the company's website at www.immucor.com . This press release may contain forward-looking statements as that term is defined in the Private Securities Reform Act of 1995, including, without limitation, statements concerning the Company's expectations, beliefs, intentions or strategies regarding the future. All forward-looking statements included in this document are based on information available to the Company on the date hereof, and the Company assumes no obligation to update any such forward-looking statements. There is no certainty that the acquired product lines will continue to generate revenues at the same level in the future. Further risks are detailed in the Company's filings with the Securities and Exchange Commission, including those set forth in the Company's most recent Form 10-K and Quarterly Reports on Form 10-Q. SOURCE Immucor, Inc. -0- 04/06/99 /CONTACT: Edward L. Gallup of Immucor, Inc., 770-441-2051/ /Web site: immucor.com / (BLUD BIPL) CO: Immucor, Inc.; Biopool International Inc. ST: Georgia IN: MTC HEA SU: TNM